A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes.

  title={A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes.},
  author={Stephen V. Faraone and Stephen J. Glatt},
  journal={The Journal of clinical psychiatry},
  volume={71 6},
  • S. Faraone, S. Glatt
  • Published 1 June 2010
  • Medicine, Psychology
  • The Journal of clinical psychiatry
OBJECTIVES Medications used to treat attention-deficit/hyperactivity disorder (ADHD) in adults have been well researched, but comparisons among drugs are hindered by the absence of direct comparative trials. Our objectives were to (1) estimate the effect size of the medications used to treat adult ADHD, (2) determine if differences in the designs of studies confound comparisons of medication efficacy, (3) quantify the evidence for differences in effect sizes among medications, and (4) see if… 

Figures and Tables from this paper

Psychopharmacology and psychotherapy for the treatment of adults with ADHD—a systematic review of available meta-analyses

The available meta-analytic literature does not cover questions of essential clinical relevance for adults with ADHD, and results suggest that stimulants are effective in decreasing ADHD symptoms on a short-term basis with a medium to large effect size (ES).

Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis

A network meta-analysis is conducted, integrating direct and indirect comparisons from randomised controlled trials (RCTs), to rank pharmacological treatments for ADHD according to their efficacy and tolerability profiles, in children or adolescents as well as in adults.

Pharmacological treatment of adult ADHD

Effect sizes from the most recent studies are calculated and they are almost identical with prior estimates, and in terms of Cohen-d typically indicate medium-to-high effect sizes for the pharmacotherapy of adult ADHD.

Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.

A systematic review of randomised clinical trials (RCTs) for methylphenidate treatment for children and adolescents with ADHD demonstrated no increase in serious adverse events, but a high proportion of participants suffered a range of non-serious adverse events.

Long-Term Efficacy of Psychosocial Treatments for Adults With Attention-Deficit/Hyperactivity Disorder: A Meta-Analytic Review

The results indicate that the post-treatment gains reported in previous reviews are sustained for at least 12 months, and psychological interventions are a highly valuable and stable clinical tool for the treatment of core symptoms and global functioning in adults with ADHD.

Pharmacological Treatment of ADHD in Addicted Patients: What Does the Literature Tell Us?

Several factors, including ADHD symptom severity, psychiatric comorbidity, persistent drug use, choice of medication, and concomitant psychosocial intervention, influence study results, and taking these factors into account may improve the likelihood of detecting significant effects in future research.

Effects of methylphenidate on executive functioning in attention-deficit/hyperactivity disorder across the lifespan: a meta-regression analysis

Results indicate that effects of MPH on executive functions are independent of age in children and adults with ADHD, however, adolescent studies are lacking and needed to conclude a lack of an age-dependency across the lifespan.



Comparing the efficacy of medications for ADHD using meta-analysis.

OBJECTIVE Medications used to treat attention-deficit/hyperactivity disorder (ADHD) have been well researched, but comparisons among drugs are hindered by the absence of direct comparative trials.

Meta-Analysis of the Efficacy of Methylphenidate for Treating Adult Attention-Deficit/Hyperactivity Disorder

Strong support is found for the assertion that MPH is efficacious for treating adult ADHD and provides further assurance to clinicians that the diagnosis of ADHD can be validly applied in adulthood.

A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults.

The results suggest a therapeutic role for bupropion in the armamentarium of agents for ADHD in adults, while further validating the continuity of pharmacological responsivity of ADHD across the lifespan.

A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder.

Clonidine may be an effective second-tier treatment for symptoms of ADHD, but it has an effect size less than that of stimulants.

Efficacy of Adderall® for Attention-Deficit/Hyperactivity Disorder: A meta-analysis

Data from the six available studies of standard release Adderall show it to be efficacious for symptoms of inattention, hyperactivity- impulsivity, and aggression, as well as global ratings.

Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis

Current best evidence supports using immediate release methylphenidate as first-line treatment for most adults with ADHD, and key gaps in evidence were academic, occupational, social functioning, cardiovascular toxicity, and longer-term outcomes.

A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders.

The effect of low-dose methylphenidate in adult ADHD patients with concomitant substance use disorders is limited, and ADHD symptoms in adults were susceptible to a distinct short-term placebo response.

Comparative Efficacy of Adderall and Methylphenidate in Attention-deficit/Hyperactivity Disorder: A Meta-Analysis

Data from the four available studies suggest that Adderall has a small but statistically significant advantage over the standard-release form of methylphenidate.